SUMMARY
# Tau ASO Therapy
## Background and Rationale
Tau antisense oligonucleotide (ASO) therapy represents a paradigm shift in Alzheimer's disease treatment, moving beyond post-translational interventions to target the fundamental source of pathogenic tau production. Traditional approaches focus on clearing existing tau aggregates through immunotherapies or small molecule inhibitors, but these strategies address the problem downstream after significant neuronal damage has already occurred. ASO therapy
METHODOLOGY NOTES
**Phase 1: Patient Recruitment and Screening (Weeks 1-8)**
• Recruit 240 patients with mild-to-moderate Alzheimer's disease (MMSE 14-26)
• Confirm tau pathology via CSF p-tau181 >19 pg/mL or tau-PET SUVr >1.3
• Exclude patients with severe hepatic/renal dysfunction, anticoagulant use
• Stratify by ApoE4 status, disease severity, and baseline CSF tau levels
• Obtain informed consent and baseline assessments
**Phase 2: Baseline Characterization (Weeks 9-12)**
• Collect CSF samples for tau quantification (p-tau181, t-tau, Aβ42/40 ratio)
• Perform comprehensive neuropsychological battery (ADAS-Cog, CDR-SB, MMSE)
• Acquire structural MRI and tau-PET imaging using [18F]flortaucipir
• Document concomitant medications and medical history
• Establish safety laboratory baseline (CBC, CMP, PT/PTT, inflammatory markers)
**Phase 3: Randomized Treatment Phase (Weeks 13-64)**
• Randomize patients 1:1:1 to tau ASO (20mg), tau ASO (40mg), or placebo
• Administer intrathecal injections every 4 weeks (